Azitra reports ATR-COSF ex vivo results: 4.4-fold elasticity increase, improved distribution

Azitra, Inc.

ATR-COSF supernatant with recombinant filaggrin showed increased penetration into stratum granulosum with multiple doses in ex vivo human skin.
Hydrogel with 7.5% w/w supernatant increased skin elasticity 4.4-fold; 0.28% w/w restored elasticity to healthy skin levels.
Safety testing confirmed 2% supernatant formulation is non-irritating and non-corrosive to skin and eyes.
CEO plans to optimize formulations and initiate human study for visible wrinkle reduction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.